Ostergaard L, Vesikari T, Senders SD, Flodmark CE, et al. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine 2021 Jun 29. pii: S0264-410X(21)00717.
PMID: 34215452